PMID- 25499371
OWN - NLM
STAT- MEDLINE
DCOM- 20150728
LR  - 20220311
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 177
IP  - 1
DP  - 2014 Nov 15
TI  - Renal function largely influences Galectin-3 prognostic value in heart failure.
PG  - 171-7
LID - S0167-5273(14)01713-6 [pii]
LID - 10.1016/j.ijcard.2014.09.011 [doi]
AB  - BACKGROUND: Galectin-3 (Gal-3) has been associated with cardiac remodeling and 
      heart failure (HF) prognosis. Renal function is also a well known HF prognostic 
      indicator. The link between renal insufficiency, HF, and Gal-3 is not completely 
      elucidated. METHODS AND RESULTS: We explored the association between Gal-3 and 
      renal function in a cohort of 876 consecutive ambulatory patients with HF (mean 
      age: 68 years; mean left ventricular ejection fraction [LVEF]: 36%), 52.2% had HF 
      etiology of ischemic heart disease. Circulating Gal-3 was highly correlated with 
      estimated glomerular filtration rate (eGFR), calculated with either the chronic 
      kidney disease-epidemiology (CKD-EPI) equation (r = -0.64) or the 
      CKD-EPI-cystatin-C equation (r = -0.59) and with Cystatin-C levels (r = 0.70), 
      after adjusting for age, sex, New York Heart Association (NYHA) functional class, 
      LVEF, and HF etiology (all p<0.001). Patients were stratified by CKD-EPI-eGFR 
      (ml/min/1.73 m(2)), as follows: >/= 60 (n = 218), 30 to 59 (n = 434), and <30 (n = 
      224). In these strata, Gal-3 significantly increased (median [IQR]: 12.3 
      [10.4-15.6]; 16.1 [13-19.8]; and 24.5 [20-33.8] ng/ml, respectively; trend p < 
      0.001). This was independent of NYHA functional class (I-II and III-IV) and LVEF 
      (<45% and >/= 45%). Gal-3 was associated with mortality in univariate analyses, but 
      after adjusting for CKD-EPI-eGFR, the hazard ratios were 1.10 (95% CI: 0.89-1.34, 
      p = 0.39) for all cause death, and 0.90 (95% CI: 0.68-1.21, p = 0.50) for 
      cardiovascular death. Similar results were obtained with eGFRs calculated with 
      the CKD-EPI-cystatin-C equation. CONCLUSION: Circulating Gal-3 was highly 
      associated with renal function in outpatients with HF. The value of Gal-3 for HF 
      prognosis declined after adjusting for renal function.
CI  - Copyright (c) 2014 Elsevier Ireland Ltd. All rights reserved.
FAU - Zamora, Elisabet
AU  - Zamora E
AD  - Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 
      Department of Medicine, Autonomous University of Barcelona, Spain.
FAU - Lupon, Josep
AU  - Lupon J
AD  - Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 
      Department of Medicine, Autonomous University of Barcelona, Spain.
FAU - de Antonio, Marta
AU  - de Antonio M
AD  - Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 
      Department of Medicine, Autonomous University of Barcelona, Spain.
FAU - Galan, Amparo
AU  - Galan A
AD  - Biochemistry Service, Hospital Universitari Germans Trias i Pujol, Badalona, 
      Spain.
FAU - Domingo, Mar
AU  - Domingo M
AD  - Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
FAU - Urrutia, Agustin
AU  - Urrutia A
AD  - Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 
      Department of Medicine, Autonomous University of Barcelona, Spain.
FAU - Troya, Maribel
AU  - Troya M
AD  - Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 
      Department of Medicine, Autonomous University of Barcelona, Spain.
FAU - Bayes-Genis, Antoni
AU  - Bayes-Genis A
AD  - Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 
      Department of Medicine, Autonomous University of Barcelona, Spain. Electronic 
      address: abayesgenis@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141011
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Biomarkers)
RN  - 0 (Galectin 3)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Cause of Death/trends
MH  - Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - Galectin 3/*blood
MH  - Glomerular Filtration Rate/*physiology
MH  - Heart Failure/blood/*complications/mortality
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Prognosis
MH  - Renal Insufficiency/blood/*etiology/physiopathology
MH  - Retrospective Studies
MH  - Risk Assessment/*methods
MH  - Spain/epidemiology
MH  - Ventricular Function, Left
OTO - NOTNLM
OT  - Biomarkers
OT  - Heart failure
OT  - Myocardial fibrosis
OT  - Remodeling
OT  - Renal failure
EDAT- 2014/12/17 06:00
MHDA- 2015/07/29 06:00
CRDT- 2014/12/16 06:00
PHST- 2014/06/02 00:00 [received]
PHST- 2014/08/08 00:00 [revised]
PHST- 2014/09/15 00:00 [accepted]
PHST- 2014/12/16 06:00 [entrez]
PHST- 2014/12/17 06:00 [pubmed]
PHST- 2015/07/29 06:00 [medline]
AID - S0167-5273(14)01713-6 [pii]
AID - 10.1016/j.ijcard.2014.09.011 [doi]
PST - ppublish
SO  - Int J Cardiol. 2014 Nov 15;177(1):171-7. doi: 10.1016/j.ijcard.2014.09.011. Epub 
      2014 Oct 11.